You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 020937


✉ Email this page to a colleague

« Back to Dashboard


NDA 020937 describes OPTIMARK, which is a drug marketed by Liebel-flarsheim and is included in three NDAs. Additional details are available on the OPTIMARK profile page.

The generic ingredient in OPTIMARK is gadoversetamide. There is one drug master file entry for this compound. Additional details are available on the gadoversetamide profile page.
Summary for 020937
Tradename:OPTIMARK
Applicant:Liebel-flarsheim
Ingredient:gadoversetamide
Patents:0

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength1654.5MG/5ML (330.9MG/ML)
Approval Date:Dec 8, 1999TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength3309MG/10ML (330.9MG/ML)
Approval Date:Dec 8, 1999TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength4963.5MG/15ML (330.9MG/ML)
Approval Date:Dec 8, 1999TE:RLD:Yes

Expired US Patents for NDA 020937

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-001 Dec 8, 1999 ⤷  Sign Up ⤷  Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-002 Dec 8, 1999 ⤷  Sign Up ⤷  Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 ⤷  Sign Up ⤷  Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-004 Dec 8, 1999 ⤷  Sign Up ⤷  Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-004 Dec 8, 1999 ⤷  Sign Up ⤷  Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.